10-Gb/s Operation of a Colorless Self-Seeded Transmitter Over More Than 70 km of SSMF

n/

Separate Evaluation of Nonlinearity-Due Q Penalties in Long-Haul Very Dense WDM Optical Systems

n/

Effect of Optical Filtering on 20-Gbit/s RZ-DQPSK Transmission over 2000 km in a 64-Channel DWDM System

n/

Self-Seeded RSOAs WDM PON Field Trial for Business and Mobile Fronthaul Applications

GEth, CPRI and 10 Gbit/s transmissions are experimented using amplified and standard self-seeded RSOA WDM PON systems. A field trial setup was exploited to test the system performance in terms of reach and optical budget

Self-Seeded RSOA-Fiber Cavity Lasers vs. ASE Spectrum-Sliced or Externally Seeded Transmitters—A Comparative Study

Reflective semiconductor optical amplifier fiber cavity lasers (RSOA-FCLs) are appealing, colorless, self-seeded, self-tuning and cost-efficient upstream transmitters. They are of interest for wavelength division multiplexed passive optical networks (WDM-PONs) based links. In this paper, we compare RSOA-FCLs with alternative colorless sources, namely the amplified spontaneous emission (ASE) spectrum-sliced and the externally seeded RSOAs. We compare the differences in output power, signal-to-noise ratio (SNR), relative intensity noise (RIN), frequency response and transmission characteristics of these three sources. It is shown that an RSOA-FCL offers a higher output power over an ASE spectrum-sliced source with SNR, RIN and frequency response characteristics halfway between an ASE spectrum-sliced and a more expensive externally seeded RSOA. The results show that the RSOA-FCL is a cost-efficient WDM-PON upstream source, borrowing simplicity and cost-efficiency from ASE spectrum slicing with characteristics that are, in many instances, good enough to perform short-haul transmission. To substantiate our statement and to quantitatively compare the potential of the three schemes, we perform data transmission experiments at 5 and 10 Gbit/s

AIRO Breast Cancer Group Best Clinical Practice 2022 Update

Introduction: Breast cancer is the most common tumor in women and represents the leading cause of cancer death. Radiation therapy plays a key-role in the treatment of all breast cancer stages. Therefore, the adoption of evidence-based treatments is warranted, to ensure equity of access and standardization of care in clinical practice.Method: This national document on the highest evidence-based available data was developed and endorsed by the Italian Association of Radiation and Clinical Oncology (AIRO) Breast Cancer Group.We analyzed literature data regarding breast radiation therapy, using the SIGN (Scottish Intercollegiate Guidelines Network) methodology (www.sign.ac.uk). Updated findings from the literature were examined, including the highest levels of evidence (meta-analyses, randomized trials, and international guidelines) with a significant impact on clinical practice. The document deals with the role of radiation therapy in the treatment of primary breast cancer, local relapse, and metastatic disease, with focus on diagnosis, staging, local and systemic therapies, and follow up. Information is given on indications, techniques, total doses, and fractionations.Results: An extensive literature review from 2013 to 2021 was performed. The work was organized according to a general index of different topics and most chapters included individual questions and, when possible, synoptic and summary tables. Indications for radiation therapy in breast cancer were examined and integrated with other oncological treatments. A total of 50 questions were analyzed and answered.Four large areas of interest were investigated: (1) general strategy (multidisciplinary approach, contraindications, preliminary assessments, staging and management of patients with electronic devices); (2) systemic therapy (primary, adjuvant, in metastatic setting); (3) clinical aspects (invasive, non-invasive and micro-invasive carcinoma; particular situations such as young and elderly patients, breast cancer in males and cancer during pregnancy; follow up with possible acute and late toxicities; loco-regional relapse and metastatic disease); (4) technical aspects (radiation after conservative surgery or mastectomy, indications for boost, lymph node radiotherapy and partial breast irradiation).Appendixes about tumor bed boost and breast and lymph nodes contouring were implemented, including a dedicated web application. The scientific work was reviewed and validated by an expert group of breast cancer key-opinion leaders.Conclusions: Optimal breast cancer management requires a multidisciplinary approach sharing therapeutic strategies with the other involved specialists and the patient, within a coordinated and dedicated clinical path. In recent years, the high-level quality radiation therapy has shown a significant impact on local control and survival of breast cancer patients. Therefore, it is necessary to offer and guarantee accurate treatments according to the best standards of evidence-based medicine

Genetic Algorithms for Structural Identification.

Millpress, Rotterdam, Netherland